MEK1/2 inhibition rescues neurodegeneration by TFEB-mediated activation of autophagic lysosomal function in a model of Alzheimer's Disease
- PMID: 35948663
- PMCID: PMC9734062
- DOI: 10.1038/s41380-022-01713-5
MEK1/2 inhibition rescues neurodegeneration by TFEB-mediated activation of autophagic lysosomal function in a model of Alzheimer's Disease
Abstract
Alzheimer's Disease (AD) is a progressive neurodegenerative disorder, which is characterized by cognitive deficit due to synaptic loss and neuronal death. Extracellular amyloid β plaques are one of the pathological hallmarks of AD. The autophagic lysosomal pathway is the essential mechanism to maintain cellular homeostasis by driving clearance of protein aggregates and is dysfunctional in AD. Here, we showed that inhibiting MEK/ERK signaling using a clinically available MEK1/2 inhibitor, trametinib (GSK1120212, SNR1611), induces the protection of neurons through autophagic lysosomal activation mediated by transcription factor EB (TFEB) in a model of AD. Orally administered trametinib recovered impaired neural structures, cognitive functions, and hippocampal long-term potentiation (LTP) in 5XFAD mice. Trametinib also reduced Aβ deposition via induction of autophagic lysosomal activation. RNA-sequencing analysis revealed upregulation of autophagic lysosomal genes by trametinib administration. In addition, trametinib inhibited TFEB phosphorylation at Ser142 and promoted its nuclear translocation, which in turn induced autophagic lysosomal related genes, indicating that trametinib activates the autophagic lysosomal process through TFEB activation. From these observations, we concluded that MEK inhibition provides neuronal protection from the Aβ burden by increasing autophagic lysosomal activity. Thus, MEK inhibition may be an effective therapeutic strategy for AD.
© 2022. The Author(s).
Conflict of interest statement
MYK and SH are inventors of PCT/KR2017/013444 and its family patent applications regarding the use of trametinib for neurodegenerative disease. MYK, TJH, and SH are stockholders of Genuv Inc. The authors declare no competing interest.
Figures





Similar articles
-
Intermittent hypoxia therapy ameliorates beta-amyloid pathology via TFEB-mediated autophagy in murine Alzheimer's disease.J Neuroinflammation. 2023 Oct 20;20(1):240. doi: 10.1186/s12974-023-02931-6. J Neuroinflammation. 2023. PMID: 37864249 Free PMC article.
-
Neuronal-Targeted TFEB Accelerates Lysosomal Degradation of APP, Reducing Aβ Generation and Amyloid Plaque Pathogenesis.J Neurosci. 2015 Sep 2;35(35):12137-51. doi: 10.1523/JNEUROSCI.0705-15.2015. J Neurosci. 2015. PMID: 26338325 Free PMC article.
-
TFEB in Alzheimer's disease: From molecular mechanisms to therapeutic implications.Neurobiol Dis. 2022 Oct 15;173:105855. doi: 10.1016/j.nbd.2022.105855. Epub 2022 Aug 27. Neurobiol Dis. 2022. PMID: 36031168 Review.
-
TFEB agonist clomiphene citrate activates the autophagy-lysosomal pathway and ameliorates Alzheimer's disease symptoms in mice.J Biol Chem. 2024 Dec;300(12):107929. doi: 10.1016/j.jbc.2024.107929. Epub 2024 Oct 24. J Biol Chem. 2024. PMID: 39454957 Free PMC article.
-
The dual and emerging role of physical exercise-induced TFEB activation in the protection against Alzheimer's disease.J Cell Physiol. 2023 May;238(5):954-965. doi: 10.1002/jcp.31005. Epub 2023 Apr 3. J Cell Physiol. 2023. PMID: 37013375 Review.
Cited by
-
Bromelain Ameliorates Atherosclerosis by Activating the TFEB-Mediated Autophagy and Antioxidant Pathways.Antioxidants (Basel). 2022 Dec 29;12(1):72. doi: 10.3390/antiox12010072. Antioxidants (Basel). 2022. PMID: 36670934 Free PMC article.
-
Trehalose enhances mitochondria deficits in human NPC1 mutant fibroblasts but disrupts mouse Purkinje cell dendritic growth ex vivo.PLoS One. 2023 Nov 30;18(11):e0294312. doi: 10.1371/journal.pone.0294312. eCollection 2023. PLoS One. 2023. PMID: 38033125 Free PMC article.
-
Trametinib activates endogenous neurogenesis and recovers neuropathology in a model of Alzheimer's disease.Exp Mol Med. 2023 Oct;55(10):2177-2189. doi: 10.1038/s12276-023-01073-2. Epub 2023 Oct 2. Exp Mol Med. 2023. PMID: 37779138 Free PMC article.
-
Artemisiae Iwayomogii Herba mitigates excessive neuroinflammation and Aβ accumulation by regulating the pro-inflammatory response and autophagy-lysosomal pathway in microglia in 5xFAD mouse model of Alzheimer's disease.Geroscience. 2025 Apr;47(2):1957-1972. doi: 10.1007/s11357-024-01388-6. Epub 2024 Oct 21. Geroscience. 2025. PMID: 39433702 Free PMC article.
-
Intermittent hypoxia therapy ameliorates beta-amyloid pathology via TFEB-mediated autophagy in murine Alzheimer's disease.J Neuroinflammation. 2023 Oct 20;20(1):240. doi: 10.1186/s12974-023-02931-6. J Neuroinflammation. 2023. PMID: 37864249 Free PMC article.
References
-
- Sala Frigerio C, De Strooper B. Alzheimer’s Disease Mechanisms And Emerging Roads To Novel Therapeutics. Annu Rev Neurosci. 2016;39:57–79. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous